Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7YBGH)

Drug Name

AL001 Drug Info

Synonyms

Latozinemab

Indication

Disease Entry	ICD 11	Status	REF
Frontotemporal dementia	6D83	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sortilin (SORT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK4527223	DMXLD07	Frontotemporal dementia	6D83	Phase 3	[3]
GSK4527226	DMOVMGA	Neurodegenerative disorder	8A20-8A23	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04374136) A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene. U.S.National Institutes of Health.
2	Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J Transl Med. 2023 Jun 15;21(1):387.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline